Clinical Trials on Hemofilia

Total 850 results

Grifols Biologicals, LLC

Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

Poland
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Terminated

Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital

United States, Spain, Italy, India, Canada, Russian Federation
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Children's Hospital Los Angeles

Withdrawn

Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography

Hemophilia A With Inhibitors
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Severe Hemophilia A

United States
Nara Medical University
Shire

Unknown

Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Hemophilia A With Inhibitor

Japan
Skane University Hospital

Completed

Hemophilia Inhibitor Genetics Study (HIGS)

Hemophilia A With Inhibitor

Sweden
Turkish Society of Hematology

Unknown

Turkish Acquired Haemophilia Registry (EHEM)

Acquired Haemophilia

Turkey
New York Presbyterian Hospital
Manchester University NHS Foundation Trust

Terminated

International Immune Tolerance Study

Hemophilia A With Inhibitors

United States
St. Jude Children's Research Hospital

Recruiting

Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy

Hemophilia B | Gene Therapy

United States
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
Baxalta now part of Shire

Active, not recruiting

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

Hemophilia B

United States
Novo Nordisk A/S

Enrolling by invitation

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Haemophilia B

Japan, Denmark
Ultragenyx Pharmaceutical Inc

Completed

Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Hemophilia B

United States, United Kingdom
Baxalta now part of Shire

Completed

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

Hemophilia A | Hemophilia B

United States, Spain, Italy, Germany, France, Austria
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, United Kingdom, Spain, Hong Kong, Israel, New Zealand, Sweden, Australia, Brazil, Japan, Austria, Belgium, Italy, India, Switzerland, Canada, France, Germany, South Africa
Spark Therapeutics
Children's Hospital of Philadelphia; University of Pittsburgh; St. James's Hospital... and other collaborators

Terminated

Hemophilia B Gene Therapy With AAV8 Vector

Hemophilia B

United States, Australia
Ultragenyx Pharmaceutical Inc

Terminated

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Hemophilia B

United States, United Kingdom, Bulgaria
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years

Haemophilia B

Poland, Ukraine
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B

Haemophilia B

United Kingdom
Equilibra Bioscience LLC

Recruiting

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)

Hemophilia A | Hemophilia B | Healthy Participants

United States
Swedish Orphan Biovitrum
Cerner Enviza

Completed

A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France (B-SURE)

Haemophilia B

France
Groupe Maladies hémorragiques de Bretagne

Completed

Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A (GIDEHAC)

Factor VIII Deficiency | Desmopressin | Carrier of Hemophilia A

France
Shanghai Belief-Delivery BioMed Co., Ltd

Active, not recruiting

Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

Hemophilia B

China
Baxalta now part of Shire

Terminated

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Hemophilia B

Turkey, Spain
Haemnet
Roche Chugai

Completed

An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families (EmiandMe)

Hemophilia A With Inhibitor

United Kingdom
University of Miami
Shire

Terminated

The Hemophilia Ultrasound Project (HUP)

Hemophilia A | Hemophilia B

United States
Cliniques universitaires Saint-Luc- Université...

Completed

Gait Evaluation in Haemophiliac Patients (GAIT_GENERAL)

Hemophilia A | Hemophilia B

Belgium
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

Haemophilia B

United Kingdom
Avigen
The University of Texas Health Science Center, Houston; Children's Hospital... and other collaborators

Terminated

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

Hemophilia B

United States
Hospices Civils de Lyon

Recruiting

Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®) (CHALE)

Hemophilia A | Hemophilia B

France
Biocad

Recruiting

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Hemophilia B

Russian Federation
St. Jude Children's Research Hospital

Not yet recruiting

Liver Biopsy Following Gene Therapy For Hemophilia

Hemophilia A | Hemophilia B

United States
Bahçeşehir University

Recruiting

Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemophilia

Hemophilia A | Hemophilia B

Turkey
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Hemophilia B
Institute of Hematology & Blood Diseases Hospital

Recruiting

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

Hemophilia B

China
Pfizer

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Hemophilia A | Hemophilia B

Hong Kong, Spain, Serbia, Turkey, United States, China, Mexico, South Africa, India, Japan, Croatia, Korea, Republic of, Oman, Taiwan, Italy, Canada, France
McMaster University

Recruiting

Personalized Medicine for Canadians With Hemophilia (PMCH)

Hemophilia A | Hemophilia B

Canada
CSL Behring

Active, not recruiting

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

Hemophilia B

Netherlands, Germany
Pfizer

Active, not recruiting

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Hemophilia A | Hemophilia B

United States, Canada, Spain, Australia, Korea, Republic of, Taiwan, Brazil, Italy, Japan, Turkey, Germany, United Kingdom, Saudi Arabia, France, Sweden, Belgium, Greece, Israel
CSL Behring

Enrolling by invitation

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

Hemophilia B

United States
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
McMaster University

Enrolling by invitation

Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability (WAPPS-Hemo)

Hemophilia A | Hemophilia B

Canada
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Hemophilia A or B With Inhibitors

Croatia, North Macedonia, Ukraine
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
CSL Behring

Completed

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Australia, Japan, France, Philippines, Spain, Czechia, Israel, Canada, Germany, Austria, Bulgaria, Italy, Malaysia, South Africa

Clinical Trials on Hemofilia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations